-
2 weeks ago | 
ascopost.com | Caroline Helwick
Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless of the tumor type, researchers from Memorial Sloan Kettering (MSK) Cancer Center reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting.1 Their findings were simultaneously published in TheNew England Journal of Medicine.2 In 2022, the same researchers reported that...
-
2 weeks ago | 
ascopost.com | Caroline Helwick
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit from specific therapies.
-
3 weeks ago | 
ascopost.com | Caroline Helwick |Chase Doyle
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.
-
1 month ago | 
ascopost.com | Caroline Helwick
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement.
-
1 month ago | 
ascopost.com | Caroline Helwick
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers of The ASCO Post.
-
1 month ago | 
ascopost.com | Caroline Helwick
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET) trial conducted in Japan.1 “Everolimus plus lanreotide has the potential to become a new standard first-line treatment of patients with unresectable or recurrent gastroenteropancreatic neuroendocrine...
-
1 month ago | 
ascopost.com | Caroline Helwick
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting.1 These patients were also significantly more likely to achieve a major pathologic response.
-
1 month ago | 
ascopost.com | Caroline Helwick
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting.1 These patients were also significantly more likely to achieve a major pathologic response.
-
2 months ago | 
ascopost.com | Caroline Helwick
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP inhibitor olaparib, in newly diagnosed patients.1 In addition, pembrolizumab plus chemotherapy, without olaparib, offered benefit in certain patient subsets not receiving the monoclonal antibody...
-
2 months ago | 
ascopost.com | Caroline Helwick
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced cervical cancer.
